Relative Bioavailability of Early Phase & Late Phase Hetrombopag Olamine

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The primary objective of the study is to evaluate the relative bioavailability of early phase and late phase hetrombopag olamine formulations in healthy Chinese adult subjects under fasting conditions. The secondary objective of the study is to evaluate the safety of hetrombopag olamine in healthy Chinese adult subjects.

See also
Status	Clinical Trial	Phase
Completed	`NCT03334084` - A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects	Phase 1
Completed	`NCT03972462` - NPC-12G Gel 0.2% Sirolimus PK Bridging Study	Phase 1
Withdrawn	`NCT02883439` - Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasone Propionate	N/A

NCT number	NCT04688008
Study type	Interventional
Source	Jiangsu HengRui Medicine Co., Ltd.
Contact
Status	Completed
Phase	Phase 1
Start date	September 18, 2020
Completion date	October 30, 2020

Relative Bioavailability of Early Phase and Late Phase Hetrombopag Olamine Formulations

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms